An intelligent control strategy for cancer cells reduction in patients with chronic myelogenous leukaemia using the reinforcement learning and considering side effects of the drug

2020 ◽  
Author(s):  
Amin Noori ◽  
Alireza Alfi ◽  
Ghazaleh Noori
Keyword(s):  
Reinforcement Learning ◽  
Side Effects ◽  
Cancer Cells ◽  
Intelligent Control ◽  
Control Strategy ◽  
Chronic Myelogenous Leukaemia ◽  
Myelogenous Leukaemia

scholarly journals Imatinib induced bone marrow hypoplasia in a case of chronic myelogenous leukemia

2019 ◽  
Vol 7 (2) ◽  
pp. 627
Author(s):  
Mehlam Kausar ◽  
Shashidhar V. Karpurmath ◽  
Manjunath I. Nandennavar ◽  
Roshan K. Jacob ◽  
Veerendra Angadi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Side Effects ◽  
Chronic Myelogenous Leukaemia ◽  
Kinase Inhibitor ◽  
Chronic Phase ◽  
Myelogenous Leukaemia ◽  
Myelogenous Leukemia ◽  
Bone Marrow Hypoplasia ◽  
First Choice ◽  
Choice Of Treatment

Imatinib mesylate a tyrosine kinase inhibitor first introduced for the treatment of chronic myelogenous leukaemia (CML) since May 2001, has revolutionised the management of CML. Imatinib is the first choice of treatment for patient with CML chronic phase (CML-CP) and generally the drug is well tolerated. A number of haematological and non-haematological side effects are associated with it. Bone marrow hypoplasia is one of the rare side effects noted with imatinib. We report a case of 46-year-old male a case of CML-CP who developed bone marrow hypoplasia following treatment with imatinib for a period of six months with bone marrow biopsy showing decreased cellularity.

Molecular Studies on Novel Antitumor Bis 1,4-Dihydropyridine Derivatives Against Lung Carcinoma and their Limited Side Effects on Normal Melanocytes

2019 ◽  
Vol 18 (15) ◽  
pp. 2156-2168 ◽  
Author(s):  
Magda F. Mohamed ◽  
Nada S. Ibrahim ◽  
Ahmed H.M. Elwahy ◽  
Ismail A. Abdelhamid
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Cells ◽  
Cell Line ◽  
Lung Carcinoma ◽  
Carcinoma Cell ◽  
Normal Cells ◽  
Lung Carcinoma Cell Line ◽  
Molecular Studies ◽  
Dihydropyridine Derivatives

Background: Cancer is a complex genetic disease which is characterized by an abnormal cell growth, invasion and spreading to other parts of the body. There are several factors that lead to cancer by causing DNA damage and the impairment of its repair. Treatment of cancer using the chemotherapeutic drugs have adverse side effects such as toxicity as they lose their specificity toward cancer cells and affect also normal cells. Moreover, the cancer cells can resist the chemotherapeutic agents and make them ineffective. For these reasons, much attentions have been paid to develop new drugs with limited side effects on normal cells and to diminish cancer resistance to drug chemotherapy. Recently, some 1,4-dihydropyridine derivatives were reported to act as Multi-Drug Resistance (MDR) modulators that inhibit p-glycoprotein which is responsible for the inability of drugs to enter the cancer cells. Also 1,4-DHPs have antimutagenic properties against chemicals via modulating DNA repair when studied on drosophila. Objective: The objective of this study is the synthesis of bis 1,4-DHPs incorporating ester as well as ether linkages and evaluate the anticancer activity of new compounds for synergistic purpose. Different genetic tools were used in an attempt to know the mechanism of action of this compound against lung cancer. Method: An efficient one pot synthesis of bis 1,4-DHPs using 3-aminocrotononitrile and bis(aldehydes) has been developed. The cytotoxic effect against human cell lines MCF7, and A549 cell lines was evaluated. Results: All compounds exhibited better cytotoxicity toward lung carcinoma cells than breast cancer cells. With respect to lung carcinoma cell line (A549), compound 10 was the most active compound and the three other compounds 7, 8, and 9 showed comparable IC50 values. In case of breast cancer cell line (MCF7), the most active one was compound 7, while compound 8 recorded the least activity. Conclusion: we have developed an efficient method for the synthesis of novel bis 1,4-dihydropyridine derivatives incorporating ester or ether linkage. All compounds showed better cytotoxicity results against A549 than MCF7, so that lung carcinoma cell line was chosen to perform the molecular studies on it. The results showed that all compounds (7, 8, 9 and 10) caused cell cycle arrest at G1 phase. The molecular docking study on CDK2 confirmed the results of cell cycle assay which showed good binding energy between the compounds and the active site of enzyme indicating the inhibition of the enzyme.

scholarly journals Robust Quadrotor Control through Reinforcement Learning with Disturbance Compensation

2021 ◽  
Vol 11 (7) ◽  
pp. 3257
Author(s):  
Chen-Huan Pi ◽  
Wei-Yuan Ye ◽  
Stone Cheng
Keyword(s):  
Neural Network ◽  
Reinforcement Learning ◽  
Control Strategy ◽  
External Disturbance ◽  
Control Agent ◽  
Network Control ◽  
Outdoor Environment ◽  
Disturbance Compensation ◽  
Tracking Accuracy ◽  
Control Scheme

In this paper, a novel control strategy is presented for reinforcement learning with disturbance compensation to solve the problem of quadrotor positioning under external disturbance. The proposed control scheme applies a trained neural-network-based reinforcement learning agent to control the quadrotor, and its output is directly mapped to four actuators in an end-to-end manner. The proposed control scheme constructs a disturbance observer to estimate the external forces exerted on the three axes of the quadrotor, such as wind gusts in an outdoor environment. By introducing an interference compensator into the neural network control agent, the tracking accuracy and robustness were significantly increased in indoor and outdoor experiments. The experimental results indicate that the proposed control strategy is highly robust to external disturbances. In the experiments, compensation improved control accuracy and reduced positioning error by 75%. To the best of our knowledge, this study is the first to achieve quadrotor positioning control through low-level reinforcement learning by using a global positioning system in an outdoor environment.

scholarly journals Burden Control Strategy Based on Reinforcement Learning for Gas Utilization Rate in Blast Furnace

2020 ◽  
Vol 53 (2) ◽  
pp. 11704-11709
Author(s):  
Xiaoling Shen ◽  
Jianqi An ◽  
Min Wu ◽  
Jinhua She
Keyword(s):  
Blast Furnace ◽  
Reinforcement Learning ◽  
Control Strategy ◽  
Utilization Rate ◽  
Gas Utilization

scholarly journals A Hybrid Tracking Control Strategy for Nonholonomic Wheeled Mobile Robot Incorporating Deep Reinforcement Learning Approach

IEEE Access ◽  
2021 ◽  
Vol 9 ◽  
pp. 15592-15602
Author(s):  
Xueshan Gao ◽  
Rui Gao ◽  
Peng Liang ◽  
Qingfang Zhang ◽  
Rui Deng ◽  
...  
Keyword(s):  
Reinforcement Learning ◽  
Mobile Robot ◽  
Control Strategy ◽  
Tracking Control ◽  
Wheeled Mobile Robot ◽  
Learning Approach

JUVENILE CHRONIC MYELOGENOUS LEUKAEMIA: THE ONLY EXAMPLE OF TRULY FETAL (NOT FETAL-LIKE) ERYTHROPOIESIS

1990 ◽  
Vol 76 (2) ◽  
pp. 307-310 ◽  
Author(s):  
Rona S. Weinberg ◽  
David Leibowitz ◽  
Mark E. Weinblatt ◽  
Joseph Kochen ◽  
Blanche P. Alter
Keyword(s):  
Chronic Myelogenous Leukaemia ◽  
Myelogenous Leukaemia

scholarly journals Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1

2001 ◽  
Vol 114 (3) ◽  
pp. 581-590 ◽  
Author(s):  
Anne Carter ◽  
Eldad J. Dann ◽  
Tamar Katz ◽  
Yael Shechter ◽  
Ana Oliven ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Chronic Myelogenous Leukaemia ◽  
Myelogenous Leukaemia

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

2013 ◽  
Vol 32 (2) ◽  
pp. 87-93 ◽  
Author(s):  
Zdenek Racil ◽  
Filip Razga ◽  
Hana Klamova ◽  
Jaroslava Voglova ◽  
Petra Belohlavkova ◽  
...  
Keyword(s):  
Clinical Evidence ◽  
Chronic Myelogenous Leukaemia ◽  
Myelogenous Leukaemia ◽  
Trough Plasma
Sign in / Sign up

Export Citation Format

Share Document